Hims & Hers Health Completes $150M Acquisition of Urbio

Why It Matters

The results show Hims & Hers can monetize a consumer‑centric digital health platform and diversify beyond weight‑loss drugs, positioning it for sustained growth in a fragmented telehealth market.

Key Takeaways

• Q1 revenue $618M, up 28% YoY.
• Subscribers exceed 2.5M, 1M net additions since 2023.
• International revenue up 400% to $134M, new markets added.
• New labs, hormone, menopause lines targeting $100M each.
• 2026 revenue guidance $2.7‑$2.9B, 15‑24% growth.

Pulse Analysis

Hims & Hers Health continues to ride the wave of digital‑health adoption, leveraging a subscription‑based model that now serves over 2.5 million members. The company’s Q1 revenue jump to $618 million and a 59% increase in full‑year sales underscore the scalability of its platform, which combines telemedicine, direct‑to‑consumer pharmaceuticals, and data‑driven engagement. Compared with traditional telehealth peers, Hims & Hers benefits from higher average revenue per user—$83 monthly—driven by cross‑selling personalized treatments and a growing share of high‑margin specialty services.

Diversification is a core theme of the earnings call. New offerings in labs, hormone therapy, and menopause have been launched within three months and are already projected to surpass $100 million in annual revenue each. By integrating AI‑enhanced diagnostics and at‑home sampling technology from the recent Urbio acquisition, the firm deepens its value proposition and improves customer retention. This strategic shift reduces reliance on GLP‑1 weight‑loss products, whose pricing volatility poses regulatory and margin risks, while opening higher‑margin pathways in preventive and chronic‑care segments.

International expansion accelerates through a series of acquisitions, notably Zava, LiveWell, and the pending Eucalyptus deal, which together broaden Hims & Hers’ footprint across Europe, Canada, Australia, and Japan. International revenue grew 400% year‑over‑year to $134 million, and management expects at least $200 million in 2026, with the Eucalyptus integration potentially adding another $200 million in the second half. These moves not only diversify geographic risk but also set the stage for the company’s 2030 ambition of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, signaling a long‑term trajectory toward market leadership in consumer‑focused healthcare.

Deal Summary

Hims & Hers Health Inc. announced the recent closing of its acquisition of Urbio, a company specializing in at‑home, pain‑free microneedle blood sampling devices, for an estimated $150 million. The deal expands Hims & Hers’ health‑tech portfolio and supports its international expansion strategy. The acquisition was disclosed during the company’s Q1 2026 earnings call.